Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Bio-Techne Corporation, commonly known as Bio-Techne, is a prominent US-headquartered life science company founded in 1976. With global operations spanning North America, Europe, and Asia, it serves the biotechnology, pharmaceutical, and clinical diagnostics industries.
Bio-Techne is a leading developer and manufacturer of high-quality reagents, analytical instruments, and services. Its comprehensive portfolio, featuring brands like R&D Systems and ProteinSimple, supports critical research in areas such as proteomics, spatial biology, and cell and gene therapy, accelerating scientific discovery and advancing healthcare solutions worldwide.
-3 vs industry average
Bio-Techne’s score of 39 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Bio-Techne, a US-based Pharmaceutical Preparation Manufacturing company, reported its Scope 1 emissions for 2024 as 3,026,000 kg CO2e and its market-based Scope 2 emissions as 15,909,000 kg CO2e. The total market-based Scope 1 and 2 emissions for 2024 were 18,935,000 kg CO2e. For 2023, Bio-Techne disclosed Scope 1 emissions of 3,001,000 kg CO2e and location-based Scope 2 emissions of 14,565,000 kg CO2e. In 2022, Scope 1 emissions were 3,781,000 kg CO2e and location-based Scope 2 emissions were 13,812,000 kg CO2e. Looking back to 2021, the company's Scope 1 emissions stood at 2,684,000 kg CO2e, with location-based Scope 2 emissions at 12,694,000 kg CO2e.
Bio-Techne is committed to climate action, having submitted a letter of commitment to reduce its Scope 1, 2, and 3 greenhouse gas emissions. These targets are awaiting validation by the Science Based Targets Initiative (SBTi) in 2026. The company is classified by the SBTi as "Committed" for near-term targets.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Bio-Techne’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more